378 related articles for article (PubMed ID: 16949783)
1. In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries.
Song JH; Ko KS; Lee MY; Park S; Baek JY; Lee JY; Heo ST; Kwon KT; Ryu SY; Oh WS; Peck KR; Lee NY
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):445-50. PubMed ID: 16949783
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of ertapenem against selected respiratory pathogens.
Marchese A; Gualco L; Schito AM; Debbia EA; Schito GC
J Antimicrob Chemother; 2004 Nov; 54(5):944-51. PubMed ID: 15472001
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries.
Lee MY; Ko KS; Oh WS; Park S; Lee JY; Baek JY; Suh JY; Peck KR; Lee NY; Song JH
Int J Antimicrob Agents; 2006 Jul; 28(1):14-8. PubMed ID: 16777383
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries.
Ko KS; Song JH; Lee MY; Park S; Kwon KT; Heo ST; Ryu SY; Oh WS; Peck KR; Lee NY
Diagn Microbiol Infect Dis; 2006 Aug; 55(4):337-41. PubMed ID: 16631337
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
11. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
12. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
Ko WC; Hsueh PR
J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial resistance among Streptococcus pneumoniae and Haemophilus influenzae isolates in the United Arab Emirates: 2004-2006.
Senok A; Al-Zarouni M; Al-Najjar J; Nublusi A; Panigrahi D
J Infect Dev Ctries; 2007 Dec; 1(3):296-302. PubMed ID: 19734608
[TBL] [Abstract][Full Text] [Related]
15. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003).
Johnson DM; Stilwell MG; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):69-74. PubMed ID: 16546341
[TBL] [Abstract][Full Text] [Related]
16. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.
Sahm DF; Brown NP; Thornsberry C; Jones ME
Postgrad Med; 2008 Sep; 120(3 Suppl 1):16-24. PubMed ID: 18931467
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005.
Thornsberry C; Brown NP; Draghi DC; Evangelista AT; Yee YC; Sahm DF
Postgrad Med; 2008 Sep; 120(3 Suppl 1):32-8. PubMed ID: 18931469
[TBL] [Abstract][Full Text] [Related]
19. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
Inoue M; Kohno S; Kaku M; Yamaguchi K; Igari J; Yamanaka K
Int J Infect Dis; 2005 Jan; 9(1):27-36. PubMed ID: 15603993
[TBL] [Abstract][Full Text] [Related]
20. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
